The article reports on the effect of the drug Zometa, zoledronic acid made by Novartis, on the suspected development of jaw osteonecrosis to patients taking or using the medicine. In the absence of data to show that Zometa led to longer survival than Ardia, the previous drug prior to Zometa by Novartis, leaders of International Myeloma Foundation started to campaign to go back and use the old drug.